Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study).

Abstract

OBJECTIVE:

Modulation of glutamatergic neurotransmission in schizophrenia by sarcosine leads to a reduction in primary negative symptoms, while its metabolic profile is safe. In order to extend research in the area, we assessed serum levels of neuropeptide Y (NPY), a hypothalamic hormone related to anxiety and depression, also involved in mechanisms inducing weight gain. Additionally, we analyzed associations between NPY concentrations and its changes with severity of symptoms and metabolic parameters.

METHODS:

A prospective 6-month, randomized, double-blind placebo-controlled trial was completed by 57 subjects with chronic schizophrenia with predominant negative symptoms and stable antipsychotic treatment. The participants received 2 g of sarcosine (n = 28) or placebo (n = 29) daily. We assessed serum NPY concentrations and severity of symptoms (with the Positive and Negative Syndrome Scale [PANSS] and Calgary Depression Scale for Schizophrenia) at the beginning of the study, after 6 weeks and 6 months.

RESULTS:

Sarcosine did not affect NPY levels in all time points. The highest decrease in NPY concentrations was observed in the subjects who were initially depressed, who became euthymic at the last visit. We noticed an improvement in the total PANSS score, and negative symptom and general psychopathology subscales in the sarcosine group, however, without any correlation with NPY levels.

CONCLUSION:

The use of sarcosine does not change NPY levels. Peripheral NPY concentrations may be related to depressive symptoms in schizophrenia.

• Authors: Dominik Strzelecki, Magdalena Kotlicka-Antczak, Bartosz Kaczmarek, Hanna Jerczyńska, Adam Wysokiński
• Journal: Human psychopharmacology (Hum Psychopharmacol) Vol. 36 Issue 3 Pg. e2770 (05 2021) ISSN: 1099-1077 [Electronic] England
• PMID: 33245168 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: © 2020 John Wiley & Sons Ltd.

Chemical References

• Antipsychotic Agents
• Neuropeptide Y
• DEAE-Dextran
• Sarcosine

Topics

• Antipsychotic Agents (therapeutic use)
• DEAE-Dextran (therapeutic use)
• Double-Blind Method
• Drug Therapy, Combination
• Humans
• Neuropeptide Y (therapeutic use)
• Prospective Studies
• Psychiatric Status Rating Scales
• Sarcosine (therapeutic use)
• Schizophrenia (drug therapy)
• Treatment Outcome